読み込み中
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
前日終値
$9.61
+$0.46 · +5.03%
日中の時刻はETです。市場データは遅延する場合があります。
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
日中レンジ
現在 $9.61
52週レンジ
現在 $9.61
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
25
割高
センチメント
66
強気
リスク
66
高リスク
モメンタム
78
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
日中レンジ
現在 $9.61
52週レンジ
現在 $9.61
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | — | 1.67万 USD |
| 売上原価 | — | — | 1044.5万 USD | — | 585.15万 USD |
| 粗利益 | — | — | −1044.5万 USD | — | −584.33万 USD |
| 研究開発 | 3337.93万 USD | 1063.8万 USD | 788.32万 USD | 160.87億 USD | 494.92万 USD |
| 販売・一般管理 | 678.8万 USD | 618.95万 USD | 637.96万 USD | 72.93億 USD | 331.34万 USD |
| 営業費用 | 4016.73万 USD | 1682.75万 USD | 845.27万 USD | 233.8億 USD | 463.29万 USD |
| 受取利息 | — | — | — | — | 4731 USD |
| 支払利息 | — | 7.68万 USD | 20.14万 USD | 2.82億 USD | 41.63万 USD |
| 減価償却費と償却費 | — | — | 2.12万 USD | 1.44万 USD | 5.67万 USD |
| 営業利益 | −4016.73万 USD | −1682.75万 USD | −1889.77万 USD | −233.8億 USD | −1056.69万 USD |
| 純利益 | −3971.91万 USD | 277.89万 USD | −1750.61万 USD | −180.62億 USD | −1197.95万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$31.00
上昇余地（222.58%）評価サンプルは3件と限定的です
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年11月28日 | 1:25 | — | — |
株式分割 | 2022年6月28日 | 1:60 | — | — |
発効済み 2025年11月28日
1:25
発効済み 2022年6月28日
1:60
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
